Double attack: pill and radiation take on lung cancer

NCT ID NCT03667820

Ongoing Disease control Sponsor: University of Texas Southwestern Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial tests combining osimertinib, a daily targeted pill, with stereotactic ablative radiation (SABR), a precise high-dose radiation, in 41 people with advanced EGFR-mutant non-small cell lung cancer. The goal is to see if this combination improves how long the cancer stays under control. Participants must have a specific EGFR mutation and be ineligible for curative surgery or standard radiation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Osimertinib (a targeted cancer pill) and stereotactic ablative radiation (precise, high-dose radiation)
What this could lead to: If successful, this combination could offer a more effective way to control advanced EGFR-mutant lung cancer, potentially delaying disease progression and extending survival.
What could go wrong: This is a small, early-phase trial with only 41 participants, so results may not apply broadly. The combination may cause side effects or not improve outcomes over osimertinib alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER (NSCLC)

Contacts and locations

Locations

City of Hope Medical Center

Duarte, California, 91010, United States
University of Texas Southwestern Medical Center

Dallas, Texas, 75390, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.